Diabetes Health in The News: Merck’s New Injectable Insulin Receives Tentative Approval

Merck’s new injectable basal insulin, LUSDUNA Nexvue, has been tentatively approved by the FDA. This biologic insulin has yet to receive full approval, however, due to a patent infringement lawsuit. Merck was sued in September 2016 by Sanofi, which has …

The post Diabetes Health in The News: Merck’s New Injectable Insulin Receives Tentative Approval appeared first on Diabetes Health.

Continue reading...